Follicular lymphoma
Conditions
Interventions
Group 2:RTX 375 mg/m2, eight week once, total 12 times + aggressive field TOMO radiotherapy
Group 1:RTX 375 mg/m2, eight week once, total 12 times
Sponsors
Sun Yat-sen Uncersity Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years old; 2. Histopathological confirmation of CD20 (+) follicular lymphoma, grade 1,2 or 3a; 3. Ann Arbor stage III; 4. life expectancy >=3 months; 5. CR efficacy was obtained by imaging evaluation after first-line chemotherapy before enrollment; 6. Normal organ function: blood routine, liver and kidney function is normal (WBC>=3.5x10^9/L, ANC>=2.0x10^9/L, HGB > 100 g/L, PLT > 90x10^12/L, ALT, AST < 2.5ULN); 7. No other anti-tumor treatment (including traditional Chinese medicine, Chinese patent medicine and steroid drugs with anti-tumor effect); 8. Understand and voluntarily participate in the experiment, and sign the informed consent; 9. The urine pregnancy test was negative in women of childbearing age before treatment, and all enrolled patients had to agree to avoid pregnancy during the study period and 6 months after discontinuation of treatment.
Exclusion criteria
Exclusion criteria: 1. Participated in other clinical trials in the last 3 months; 2. Grade 3b follicular lymphoma; 3. Ann Arbor stage I/II or IV; 4. Serious mental illness; 5. Primary testicular lymphoma; 6. Rituximab allergy; 7. Previous or concurrent combination of other malignant tumors, except for the cured basal cell carcinoma; 8. Active infections that require treatment; 9. Organ dysfunction, such as: malignant hypertension, heart failure, dilated cardiomyopathy, unstable angina or myocardial infarction within 6 months, renal insufficiency (Cr > 1.5 ULN), liver dysfunction (AST/ALT > 2.5ULN, or BIL > 2.0mg/dl); 10. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free 5 years survival; | — |
Countries
China
Contacts
Public ContactTongyu Lin
Sun Yat-sen Uncersity Cancer Center
Outcome results
None listed